癌性贫血的最新临床研究进展

癌性贫血是影响癌症患者生活质量和预后的重要因素。癌性贫血在实体瘤和血液系恶性肿瘤中的发病率很高,而放化疗进一步加重贫血的发生率和严重程度。癌性贫血的治疗方法主要包括输血、红细胞生成刺激因子疗法、补充铁剂以及更改放化疗方案。其中红细胞生成刺激因子疗法是目前最重要的治疗方法,促红细胞生成素EPO则是目前最常用的红细胞生成刺激因子。然而EPO疗法本身还存在很多争议。通过大规模临床试验,EPO治疗癌性贫血取得了很多最新的共识。到目前为止,EPO治疗癌性贫血的主要目的在于改善患者生存质量、减少输血需求。

The Update Clinical research advancement of cancer and treatment relafed anemia

For cancer patients,treatment related anemia is a debilitating problem that negatively influences their overall quality of life(QOL) and prognosis.The morbility of this condition in solid tumor and hematologic malignancies is high and further worsen by cytotoxic treatment such as chemoradiotherapy.The main treatments for anemia with cancer include transfusion of red blood cells,erythropoiesis stimulating agents(ESA),supplement of iron agents and change of toxic regimens.ESAs therapy is the most important one among these methods.Erythropoietin(EPO) is the most common used ESA agent,however,it remains controversial in many respects.Large amounts of clinical trails produce evidence-based guidelines on the use of EPO in anemic patients with cancer in recent years.Up to date,the major goals of EPO therapy are improvement of QOL and reduction of transfusions.